NSE ALKEM · BSE 539523 · Biotechnology & Drugs · NIFTY 500
Alkem Laboratories Share Price
₹5,274.00
▼ −₹60.28 · 1.13%
Day range · 25 Sep
₹5,240.00Low₹5,313.20High
52-week range
₹5,052.05Low · 11 Sep 2026₹5,933.00High · 13 Jan 2026
Alkem Laboratories Overview
Where the price stands, how it has moved and how it sits against its averages.
Alkem Laboratories shares last traded at ₹5,274.00 on the NSE, down 1.13% on the day. That is 11.1% below the 52-week high of ₹5,933.00 and 4.4% above the 52-week low of ₹5,052.05. The stock trades at 29.21× earnings, below the sector average of 33.72. Its market value is ₹63,010 Cr.
Price returns
1 Day▼ −1.13%
1 Week0.00%
This month▼ −1.04%
3 Months▼ −2.78%
6 Months▼ −1.32%
This year▼ −4.22%
1 Year▼ −4.25%
Against the market: 1 Month ▲ +2.98% · 3 Months ▲ +1.43% · 6 Months ▼ −1.74% · This year ▲ +10.46% · 1 Year ▲ +5.16%
Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Fri 16 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.
Moving averages — price is above 1 of 6
- 300-day average₹5,497.89 ▼ price 4.1% below
- 100-day average₹5,445.64 ▼ price 3.2% below
- 50-day average₹5,429.57 ▼ price 2.9% below
- 5-day average₹5,342.60 ▼ price 1.3% below
- 10-day average₹5,295.15 ▼ price 0.4% below
- Today's price₹5,274.00
- 20-day average₹5,261.48 ▲ price 0.2% above
Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.
Alkem Laboratories Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
14,712
2,302
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹14,712 Cr | ▲ +13.5% | ₹2,302 Cr | 15.6% | ₹192.51 | ₹53.00 |
| FY 2025 | ₹12,965 Cr | ▲ +2.3% | ₹2,165 Cr | 16.7% | ₹181.11 | ₹45.00 |
| FY 2024 | ₹12,668 Cr | ▲ +9.2% | ₹1,796 Cr | 14.2% | ₹150.19 | ₹40.00 |
| FY 2023 | ₹11,599 Cr | ▲ +9.1% | ₹984 Cr | 8.5% | ₹82.31 | ₹25.00 |
| FY 2022 | ₹10,634 Cr | ▲ +20.0% | ₹1,646 Cr | 15.5% | ₹137.63 | ₹34.00 |
| FY 2021 | ₹8,865 Cr | ▲ +6.2% | ₹1,585 Cr | 17.9% | ₹132.57 | ₹30.00 |
| FY 2020 | ₹8,344 Cr | — | ₹1,127 Cr | 13.5% | ₹94.26 | ₹25.00 |
4,001
3,740
765
520
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹3,740 Cr | ▲ +3.8% | ₹520 Cr | 13.9% | ₹43.49 |
| Q4 FY26 | ₹3,603 Cr | ▼ −3.6% | ₹236 Cr | 6.6% | ₹19.78 |
| Q3 FY26 | ₹3,737 Cr | ▼ −6.6% | ₹636 Cr | 17.0% | ₹53.19 |
| Q2 FY26 | ₹4,001 Cr | ▲ +18.7% | ₹765 Cr | 19.1% | ₹63.99 |
| Q1 FY26 | ₹3,371 Cr | ▲ +7.2% | ₹664 Cr | 19.7% | ₹55.56 |
| Q4 FY25 | ₹3,144 Cr | ▼ −6.8% | ₹306 Cr | 9.7% | ₹25.58 |
| Q3 FY25 | ₹3,374 Cr | ▼ −1.2% | ₹626 Cr | 18.5% | ₹52.34 |
| Q2 FY25 | ₹3,415 Cr | — | ₹689 Cr | 20.2% | ₹57.60 |
Balance sheet — FY26
Owes (liabilities)Shareholders' equity
34%
66%
- Total assets₹20,873 Cr
- Total liabilities₹7,053 Cr
- Shareholders' equity₹13,820 Cr
- Total debt₹2,047 Cr
- Cash & investments₹4,061 Cr
- Current ratio2.55×
- Revenue growth, 5 yr10.66% a year
- EPS growth, 5 yr7.75% a year
- Operating margin (TTM)16.24%
- Net margin (TTM)14.62%
Cash flow — FY26
Operating activities
▲ ₹1,963 Cr
Investing activities
▼ −₹1,667 Cr
Financing activities
▼ −₹503 Cr
Free cash flow
▲ ₹1,346 Cr
Net change in cash
▼ −₹222 Cr
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 8,344.36 | 8,865.01 | 10,634.19 | 11,599.26 | 12,667.58 | 12,964.52 | 14,712.27 |
| Cost of revenue | 3,419.54 | 3,719.06 | 4,426.78 | 5,094.38 | 5,190.71 | 5,013.72 | 5,297.24 |
| Gross profit | 4,924.82 | 5,145.95 | 6,207.41 | 6,504.88 | 7,476.87 | 7,950.80 | 9,415.03 |
| Operating expenses | 7,057.36 | 7,195.53 | 8,862.68 | 10,320.11 | 10,681.06 | 10,796.71 | 12,189.32 |
| Operating income | 1,287.00 | 1,669.48 | 1,771.51 | 1,279.15 | 1,986.52 | 2,167.81 | 2,522.95 |
| Depreciation | 252.76 | 274.58 | 303.96 | 310.42 | 299.30 | 357.16 | 382.06 |
| Profit before tax | 1,259.79 | 1,842.10 | 1,844.28 | 1,304.77 | 2,023.13 | 2,526.41 | 2,868.92 |
| Tax | 110.48 | 224.33 | 163.96 | 297.96 | 211.67 | 311.03 | 517.76 |
| Net profit | 1,127.07 | 1,585.02 | 1,645.62 | 984.17 | 1,795.77 | 2,165.48 | 2,301.80 |
| EPS (₹) | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 |
| Dividend per share (₹) | 25.00 | 30.00 | 34.00 | 25.00 | 40.00 | 45.00 | 53.00 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 9,945.54 | 11,519.26 | 14,069.19 | 13,756.63 | 15,574.90 | 17,691.10 | 20,872.97 |
| Current assets | 5,505.65 | 6,928.82 | 8,435.43 | 8,729.68 | 10,411.58 | 10,945.82 | 12,210.52 |
| Cash & short-term investments | 460.29 | 1,753.70 | 1,313.03 | 1,143.16 | 3,802.32 | 3,777.92 | 4,061.45 |
| Inventory | 1,883.89 | 2,331.73 | 3,063.01 | 2,728.93 | 2,783.39 | 3,053.07 | 3,448.99 |
| Property, plant & equipment | 2,774.14 | 2,706.43 | 2,765.93 | 2,513.52 | 2,557.03 | 2,862.70 | 3,228.54 |
| Total liabilities | 3,784.87 | 4,142.53 | 5,431.29 | 4,711.34 | 5,262.84 | 5,706.23 | 7,052.87 |
| Current liabilities | 3,244.58 | 3,604.05 | 4,805.34 | 3,707.15 | 3,994.55 | 3,966.96 | 4,782.70 |
| Total debt | 1,722.67 | 1,791.98 | 2,668.19 | 1,396.68 | 1,418.41 | 1,380.90 | 2,047.16 |
| Total equity | 6,160.67 | 7,376.73 | 8,637.90 | 9,045.29 | 10,312.06 | 11,984.87 | 13,820.10 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 585.08 | 1,264.90 | 1,111.02 | 1,682.50 | 1,948.07 | 1,912.84 | 1,963.03 |
| From investing | −741.35 | −998.54 | −1,435.13 | 112.84 | −1,008.50 | −1,298.76 | −1,667.21 |
| From financing | 79.15 | −271.75 | 379.57 | −1,760.82 | −1,145.01 | −810.99 | −503.40 |
| Capital expenditure | −363.09 | −194.91 | −338.88 | −232.91 | −259.29 | −675.62 | −617.26 |
| Dividends paid | −439.56 | −334.78 | −421.91 | −529.52 | −540.49 | −504.62 | −613.70 |
| Net change in cash | −73.11 | −1.72 | 57.96 | 41.62 | −207.49 | −186.40 | −222.04 |
Alkem Laboratories vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield |
|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories This stock | ₹5,274.00 | ▼ −1.13% | ₹63,010 Cr | 29.21 | 4.56 | 17.58% | 14.62% | 1.00% |
| Sun Pharmaceutical Industries | ₹1,853.50 | ▲ +0.03% | ₹4,44,706 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% |
| Divi's Laboratories | ₹9,610.00 | ▼ −0.03% | ₹2,55,115 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% |
| Torrent Pharmaceuticals | ₹4,985.00 | ▲ +1.01% | ₹1,89,607 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% |
| Cipla | ₹1,397.20 | ▼ −0.48% | ₹1,12,874 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% |
| Zydus Lifesciences | ₹1,202.00 | ▲ +1.86% | ₹1,19,900 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% |
Peer prices and ratios as last reported by the data provider. Company names link to their own pages.
Alkem Laboratories Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Alkem LaboratoriesBenchmarkRule-of-thumb bands
Valuation The price against earnings, book value and sales
P/E (TTM)Price ÷ yearly earnings per share
29.21
▼ 13% below the sector average of 33.72
P/E, 12-month rangeLow 24.19 · high 41.26
29%
Today's P/E sits 29% of the way from its low to its high
P/BPrice ÷ book value per share
4.56
P/SMarket cap ÷ last 12 months' revenue
4.18
P/CFPrice ÷ cash flow per share
24.26
PEGP/E ÷ earnings growth rate
0.89
Profitability Of every ₹100 of sales, how much is kept?
Gross marginKept after the cost of goods
66.03%
▲ above its 5-yr average of 60.01%
Operating marginKept after running costs
16.24%
▲ above its 5-yr average of 15.55%
Pre-tax marginKept before tax
19.03%
▲ above its 5-yr average of 16.89%
Net marginKept as profit
14.62%
▲ above its 5-yr average of 14.49%
Returns & efficiency How well does it use its money?
Return on equityProfit on shareholders' money
17.84%
▲ above its 5-yr average of 17.58%
Return on assetsProfit on everything it owns
12.19%
▲ above its 5-yr average of 11.73%
Return on investmentProfit on long-term capital
16.31%
▼ below its 5-yr average of 16.54%
Return on capital employedProfit before interest and tax on equity + debt
19.63%
Growth Is the business getting bigger?
Revenue — last 12 months
+13.4%
▲ growing
Revenue — 3 yr, a year
+8.3%
▲ growing
Revenue — 5 yr, a year
+10.7%
▲ growing
Net profit — 3 yr, a year
+32.7%
▲ growing (off the scale)
Net profit — 5 yr, a year
+7.7%
▲ growing
EPS — last 12 months
−5.6%
▼ shrinking
EPS — 3 yr, a year
+32.7%
▲ growing (off the scale)
EPS — 5 yr, a year
+7.8%
▲ growing
Dividend — 3 yr, a year
+28.5%
▲ growing (off the scale)
Book value — 5 yr, a year
+13.4%
▲ growing
Financial strength Can it pay its bills and debts?
Debt to equityBorrowings for every ₹1 of shareholders' money
0.15×
Current ratioShort-term assets for every ₹1 due within a year
2.55×
Quick ratioLike the current ratio, without inventory
1.83×
Interest coverOperating profit ÷ interest to pay
14.68×
Payout ratioShare of profit paid as dividend
27.53%
Per share What each share stands for
EPS (TTM)
₹180.45
Book value
₹1,155.53
Cash flow
₹217.35
Dividend
₹53.00
Revenue
₹1,261.34
The share price is 4.56× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 111 metrics from the data provider
Valuation
P/E excluding extraordinary items, most recent fiscal year27.40
Current Dividend Yield - Common Stock Primary Issue, LTM1.00
Price to Book - most recent fiscal year4.56
P/E Basic excluding extraordinary items - TTM30.87
P/E including extraordinary items - TTM29.23
P/E excluding extraordinary items low, trailing 12 months24.19
Price to Tangible Book - most fiscal year4.89
Dividend Yield - 5 Year Average0.89
Price to sales - most recent fiscal year4.29
Dividend Yield - indicated annual dividend divided by closing price1.00
Price to Cash Flow per share - trailing 12 month24.26
Peg Ratio0.89
Price to Free Cash Flow per Share - most recent fiscal year86.14
P/E Normalized, most recent fiscal year25.78
P/E excluding extraordinary items high, trailing 12 months41.26
P/E excluding extraordinary items, most recent fiscal year quarter29.23
Price to sales - trailing 12 month4.18
Net Debt, LFY−20,142.90
Per share
Dividend Per Share - 5 year average39.40
Cash Flow per share - trailing 12 month217.35
Cash Flow per share - most recent fiscal year228.60
EPS including extraordinary items - trailing 12 month180.45
EPS including extraordinary items - most recent fiscal year192.51
EBITD per share - trailing 12 month253.60
Revenue/share - trailing 12 month1,261.34
EPS excluding extraordinary items - trailing 12 month180.45
EPS Basic excluding extraordinary items - most recent fiscal year192.51
EPS Basic excluding extraordinary items - trailing 12 month180.45
Book value per share - most recent fiscal year1,155.87
Dividend per share - most recent fiscal year53.00
Revenue/share - most recent fiscal year1,230.48
EPS Normalized - most recent fiscal year204.60
Book value (tangible) per share - most recent fiscal year1,078.56
Dividends per share - trailing 12 month53.00
EPS excluding extraordinary items - most recent fiscal year192.51
Cash per share - most recent fiscal year339.69
Margins
Operating margin - trailing 12 month16.24
Gross Margin - 5 year average60.01
Operating margin - 1st historical fiscal year17.15
Operating Margin - 5 year average15.55
Net Profit Margin % - 1st historical fiscal year15.98
Gross Margin - 1st historical fiscal year63.99
Net Profit Margin % - trailing 12 month14.62
Net Profit Margin - 5 year average14.49
Pretax Margin - 5 year average16.89
Pretax margin - 1st historical fiscal year19.50
Pretax margin - trailing 12 month19.03
Free Operating Cash Flow/Revenue, 5 Year Average6.21
Gross Margin - trailing 12 month66.03
Growth
EPS Change %, TTM over TTM−5.56
Revenue growth rate, 5 year10.66
EPS growth rate, 5 year7.75
Revenue Change % - most recent quarter 1 year ago10.95
Growth rate% - dividend, 3 year28.46
Growth rate% - EPS, 3 year32.74
Revenue/share (5 yr growth)10.66
Free Operating Cash Flow, 5 Year CAGR−0.09
Tangible Book Value, Total Equity, 5 Year CAGR13.33
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR8.53
Capital Spending growth rate, 5 year25.93
Revenue Change %, TTM over TTM13.36
Growth rate% - Revenue, 3 year8.25
Book value per share growth rate, 5 year13.38
EPS Change % - most recent quarter 1 year ago−21.72
Net Profit Margin growth rate, 5 year−2.62
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR9.64
Total Debt, 5 Year CAGR2.70
Financial strength
Free Cash Flow - most recent fiscal year7,320.70
LT debt/equity - most recent fiscal year0.06
Quick ratio - most recent fiscal year1.83
Payout ratio - trailing 12 month5.54
Current ratio - most recent fiscal year2.55
Current EV/Free Cash Flow, LFY40.99
Total debt/total equity - most recent fiscal year0.15
Net Interest coverage - trailing 12 month14.68
Payout ratio - most recent fiscal year31.69
Returns & efficiency
Return on average equity - 5 year average17.58
Net Income/employee - trailing 12 month11,39,373.00
Revenue/employee - most recent fiscal year77,45,746.00
Return on investment - most recent fiscal year16.31
Return on average assets - most recent fiscal year12.19
Receivables turnover - most recent fiscal year5.34
Inventory turnover - most recent fiscal year1.63
Revenue/employee - trailing 12 month77,95,555.00
Return on average assets - 5 year average11.73
Net Income/employee - most recent fiscal year12,37,844.00
Asset turnover - most recent fiscal year0.76
Return on average equity - most recent fiscal year17.84
Return on investment - 5 year average16.54
Price & volume
Market Cap63,010.16
52 week Low Date11 Sep 2026
Price - 1 Day % Change−0.98
Relative (S&P500) price percent change - 13 week1.43
Avg trading volume last 10 days0.19
Price - 13 week price percent change−2.78
Price - 52 week price percent change−4.25
Avg Trading Volume Last 3 months3.15
Price - 5 Day % Change−3.52
Price % Change Month To Date−1.04
Relative (S&P500) price percent change - 04 week2.98
52 week High Date13 Jan 2026
Price - 26 week price percent change−1.32
PDATE25 Sep 2026
Price - YTD price percent change−4.22
Relative (S&P500) price percent change - 52 week5.16
NPRICE5,274.00
Relative (S&P500) price percent change - 26 week−1.74
52 week Low5,051.00
52 week High5,933.50
Beta0.75
Relative (S&P500) price percent change - Year to Date10.46
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
₹53.00
- Dividend yield1.00%
- Payout ratio27.53%
- 5-year average dividend₹39.40 a share
- Latest dividend₹10.00 per share · 7 Aug 2026
Corporate calendar
- MeetingAnnual General Meeting
- MeetingCOM
- BoardQuarterly Results
- Dividend₹10.00 per share · 500% · Final dividend
- BoardAudited Results & Final Dividend
- Dividend₹43.00 per share · 2,150% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- BoardQuarterly Results
Show 14 older events
- MeetingAnnual General Meeting
- BoardQuarterly Results
- Dividend₹8.00 per share · 400% · Final dividend
- MeetingPostal Ballot
- MeetingPostal Ballot
- BoardAudited Results & Final Dividend
- Dividend₹37.00 per share · 1,850% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- BoardQuarterly Results
- MeetingPostal Ballot
- Dividend₹5.00 per share · 250% · Final dividend
- Dividend₹35.00 per share · 1,750% · Interim dividend
- Dividend₹10.00 per share · 500% · Final dividend
- Dividend₹15.00 per share · 750% · Interim dividend
About Alkem Laboratories
Biotechnology & Drugs
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Key people
- Basudeo Narain SinghExecutive Chairman of the Board
- Nitin AgrawalPresident - Finance, Chief Financial Officer
- Manish NarangPresident - Legal, Compliance Officer, Company Secretary
- Sandeep SinghManaging Director, Executive Director
- Madhurima SinghExecutive Director
- Mritunjay Kumar SinghExecutive Director
Company facts
- NSE symbolALKEM
- BSE code539523
- ISININE540L01014
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹63,010 Cr
- Revenue (FY26)₹14,712 Cr
- Net profit (FY26)₹2,302 Cr
In the News
Recent headlines about Alkem Laboratories — they open on Mint in a new tab.
- Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
20 Jul 2026 · 2 min read · Mint ↗
Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →
Frequently Asked Questions
Alkem Laboratories (NSE: ALKEM) last traded at ₹5,274.00 on the NSE, down 1.13% (₹60.28) on the day, as of 25 Sep 2026, 10:29 AM IST. On the BSE it was ₹5,269.95. The day's range was ₹5,240.00 – ₹5,313.20.
Alkem Laboratories's 52-week high is ₹5,933.00 (13 Jan 2026) and its 52-week low is ₹5,052.05 (11 Sep 2026). At ₹5,274.00 the share is 11.1% below its high and 4.4% above its low.
Alkem Laboratories's market capitalisation is ₹63,010 Cr (₹63,010 Cr). It is part of the NIFTY 500 index.
Alkem Laboratories's P/E ratio (trailing 12 months) is 29.21. The sector average is 33.72, so investors pay 13% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹180.45.
Alkem Laboratories shares are down 4.25% over the last year, down 4.22% so far this year, down 1.32% over 6 months, down 2.78% over 3 months. Over the last year the stock did 5.16% better than the market.
In FY26 (year to Mar 2026), Alkem Laboratories reported revenue of ₹14,712 Cr (up 13.48% on the year before) and a net profit of ₹2,302 Cr. Earnings per share were ₹192.51.
Yes. Alkem Laboratories's latest dividend is ₹10.00 per share (500%, final dividend), with an ex-date of 7 Aug 2026. The dividend yield is 1.00%. It has paid 8 dividends in the records shown on this page.
As of Jun 2026: Promoter 49.70%, FII 10.42%, MF 16.71%, Other 23.17%. Promoter holding fell by 1.50 percentage points from Mar 2026.
Alkem Laboratories's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.
No. Alkem Laboratories has debt — its debt-to-equity ratio is 0.15 and total debt was ₹2,047 Cr in FY26.